The successful development of any protective vaccine requires a knowledge of the immune correlates of protection. Rational targets for vaccine-elicited immune responses can only be es-tablished with an understanding of the immune responses that provide protection against infection by a pathogen. Defining such immune correlates of protection against HIV has proven extraordinarily difficult. Although powerful nonhuman pri-mate models for HIV infection exist, impressive protection against AIDS virus challenges in these models has been diffi-cult to achieve using safe, traditional vaccine strategies (1). Therefore, the results of studies done in nonhuman primates do not allow us to state with any degree of confidence whether humoral or cellular...
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV...
Considerable progress has been made recently in understanding the genetic, immunologic and virologic...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
HIV-1 is the leading cause of death in sub-Saharan Africa, responsible for one in five deaths in the...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain u...
The definitive version is available at www.blackwell-synergy.comA large number of experimental studi...
Since the identification of the Human Immunodeficiency Virus type 1 (HIV-1) as the etiologic agent o...
In the global AIDS epidemic, over half of all infections have occurred in people less than 25 years ...
PURPOSE OF REVIEW: The only unequivocal correlate of protection against primate immunodeficiency vir...
Numerous reports indicate that human immunodeficiency virus (HIV)-exposed individuals from several h...
The field of vaccinology began in ignorance of how protection was instilled in vaccine recipients. T...
A prophylactic vaccine for HIV-1 is badly needed. Despite 20 years of effort, it is still a long way...
A major challenge for the development of a highly effective AIDS vaccine is the identification of me...
The properties of human immunodeficiency virus type 1 (HIV-1) and its simian counterpart SIV that en...
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV...
Considerable progress has been made recently in understanding the genetic, immunologic and virologic...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
HIV-1 is the leading cause of death in sub-Saharan Africa, responsible for one in five deaths in the...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain u...
The definitive version is available at www.blackwell-synergy.comA large number of experimental studi...
Since the identification of the Human Immunodeficiency Virus type 1 (HIV-1) as the etiologic agent o...
In the global AIDS epidemic, over half of all infections have occurred in people less than 25 years ...
PURPOSE OF REVIEW: The only unequivocal correlate of protection against primate immunodeficiency vir...
Numerous reports indicate that human immunodeficiency virus (HIV)-exposed individuals from several h...
The field of vaccinology began in ignorance of how protection was instilled in vaccine recipients. T...
A prophylactic vaccine for HIV-1 is badly needed. Despite 20 years of effort, it is still a long way...
A major challenge for the development of a highly effective AIDS vaccine is the identification of me...
The properties of human immunodeficiency virus type 1 (HIV-1) and its simian counterpart SIV that en...
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV...
Considerable progress has been made recently in understanding the genetic, immunologic and virologic...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...